Evaluating GT Biopharma, Inc. as an investment requires analyzing its clinical-stage immuno-oncology pipeline, specifically its proprietary TriSpecific killer cell engager (TKCE) technology platform. Small-cap immunotherapy developers typically carry high financial risks, binary clinical trial outcomes, and substantial capital needs. What is your risk tolerance and portfolio diversification strategy? Consulting a licensed financial advisor is strongly recommended.